Nuvation Bio
Closed (deSPAC)Health Care · biopharmaceutical company · founded 2018
- What it is
- Bio Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates
- What it’s doing now
- Merging with Panacea Acquisition Corp (NUVB) — closed (despac).
- What you should know
- Data is still being assembled for this company — what is shown below is everything we have verified so far.
The business, per its filings
SEC primaryBio Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bios proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the worlds leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco. For more information, please visit www.nuvationbio.com .
Source: S-4/A, accession 0001193125-21-010705
What the company says about itself
Web research — not auditedNuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment. The company aims to develop and commercialize new generations of oncology medicines that improve patient lives by addressing drug resistance or limited efficacy of current therapies.
- Markets:
- Oncology
- Products:
- Safusidenib
Source: https://nuvationbio.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.
The deal it’s entering
Nuvation Bio is merging with Panacea Acquisition Corp (NUVB) currently marked Closed (deSPAC).
| Headline equity value | — |
| PIPE | ≈ $25M · unsourced |
Structure per SEC accession(s) 0001193125-20-291761. How to read these numbers: headline vs effective valuation · what a definitive agreement commits
What exactly is being valued, and at what
Common questions
Is Nuvation Bio going public?
Nuvation Bio has an approved merger with the SPAC Panacea Acquisition Corp (NUVB). Deal status: Closed (deSPAC).
Does Nuvation Bio have revenue?
The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.
Educational content, not investment advice.
- Oak Hill Bio — with RACC ($160M) · pre-revenue
- Longevity Biomedical — with FTII ($100M) · pre-revenue
- GNQ Insilico — with IBAC ($500M)
- HCC Healthcare Pte. — with RFAM ($500M)
- OmniAb — with AHPA
- Jasper Therapeutics — with AMHC
- PANA — Panacea Acquisition Corp. II · Liquidated